Dear Customers and Partners
We are pleased to announce that QVQ, a company based in Utrecht (The Netherlands), is now a sister company of RD-Biotech SAS, Diaclone SAS and SynAbs SA (Biotech Investissement Group – www.mabexperts.com).
QVQ has strong expertise in the development and production of single domain antibodies derived from llamas, which are referred to as VHHs. VHHs have unique biochemical properties due to their small size and high stability which make them very useful for tumour targeting particularly in imaging technologies and companion diagnostics. QVQ offers multiple services related to development, reformatting and optimization of VHHs with respect to stability, production levels and humanization. Besides contract research and services, QVQ has developed a growing portfolio of proprietary detection/imaging VHHs directed against targets in disease related with oncology, age disease and infectious diseases.
By joining the Biotech Investissement group, QVQ will complement the high level of expertise already present within the group, to develop and market new high-quality diagnostic assays and imaging products.
Please do not hesitate to get in touch if you require information about the QVQ products and services.
Philippe Dulieu, CEO
Phone +33(0)3 81 53 88 37 – Mail : firstname.lastname@example.org